Navigation Links
Overfishing threatens European bluefin tuna
Date:11/7/2008

ing season early because 6 EU countries already had caught their share of the 2008 quota and because the fishing capacity of EU countries is so large that according to the EU there is a real risk of overfishing.

Bluefin tuna in Denmark

There used to be bluefin tuna in waters near Denmark. They were so abundant and landings so high that the first tuna cannery could be opened in 1929 at Skagen. In the 1950s, bluefin tuna weighing 100 kg and more were often caught with hooks in the resund and Kattegat. When the fishery in northern European waters (mainly the North and Norwegian Seas) was at its high point in the mid-1950s, fishermen in Norway, Denmark, Germany and Sweden landed in total ca. 15,000 tonnes per year. But the "tuna adventure" ended in the mid-1960s. Today bluefin tuna are extremely rare in the North Sea and Norwegian Sea.


'/>"/>

Contact: Kira Paulli Pravato
kpp@ruc.dk
454-674-3222
Census of Marine Life
Source:Eurekalert

1

GOOD

Page: 1 2 3

Related biology news :

1. Global warming threatens Australias iconic kangaroos
2. Climate change threatens 1 in 5 plant species
3. Study: Future snowmelt in West twice as early as expected; threatens ecosystems and water reserves
4. Plague of kangaroos threatens one of Australias last remaining original native grasslands
5. Logging road threatens rare peat dome, tigers
6. Global trade in tiger shrimp threatens environment
7. Starfish outbreak threatens corals
8. European biodiversity and ecosystem scientists merge and gear up for long-term research
9. The MDS foundation supports vidazas recommendation for European approval
10. Vidaza receives positve opinion from European CHMP
11. European researchers harness unique properties of boron to develop new drugs and diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):UCLA researchers engineer bacteria to turn carbon dioxide into liquid fuel 2University of California, San Francisco, researcher receives ASBMB-Merck Award 2CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 1CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 2CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 3CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 4CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 5CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 6CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 7CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 8CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 9CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 10CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 11CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 12CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 13CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 14CryoLife Reports Record Quarterly Revenues of 2428 2 Million 5824 15Global Spinal Nonfusion Market to Reach Almost 242 Billion By 2013 According to Millennium Research Group 5822 1Global Spinal Nonfusion Market to Reach Almost 242 Billion By 2013 According to Millennium Research Group 5822 2Global Spinal Nonfusion Market to Reach Almost 242 Billion By 2013 According to Millennium Research Group 5822 3Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 1Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 2Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 3Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 4Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 5Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 6Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 7Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 8Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 9Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 10Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 11Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 12Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 13Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 14Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full Year Financial Guidance 5820 15